Another year on AIM is almost over and with it, this article offers a new reminder that backing the market’s smallest companies is not for the faint-hearted but the gains can be huge.
The rules are different down here: volatility is the default setting, visibility is often low, and the gap between boom and bust can be measured in trading sessions.
But that’s the deal, and most punters know it. For every lead balloon, there can be a skyrocket and 2025 was no exception.
AIM’s standout performers in 2025 were defined by a series of transformational deals, technical breakthroughs, and exploration milestones that drove significant — and in some cases sudden — re-ratings in share prices.
Fiinu led the gains, with shares surging nearly 1,500% in January after it announced non-binding heads of terms for a white-label agreement with a UK bank to deploy its 'Plugin Overdraft' product. The deal would integrate Fiinu’s banking-as-a-service platform into the partner’s existing systems, with a product launch targeted for the fourth quarter of 2025.
“The Bank Independent Overdraft platform will fully integrate into the bank's existing treasury, regulatory reporting and accounting systems,” the company said.
Momentum continued in August as Fiinu revealed a reverse takeover of FX brokerage Everfex, a profitable business with more than $1 billion in contracts executed in 2024. The shares, which started the year at 0.5%, briefly hit 21p in the summer, were just below 10p as year-end neared.
Strategic Minerals saw its share price spike in October following drill results from its Redmoor tungsten-tin-copper project in Cornwall. A nine-hole campaign is already confirming the full thickness of the sheeted vein system and demonstrated strong mineralisation across multiple veins.
Last month, the company said that once all assay results are received, an updated mineral resource estimate will be completed in early 2026. With current market prices for tungsten, tin and copper have strengthened since the 2020 scoping study, management have expressed confidence in the project’s long-term value, seeing Redmoor as one of the highest-grade tungsten projects globally.
Mkango Resources rallied in July on news of a US$400 million merger to form Mkango Rare Earths Limited, a Nasdaq-listed company combining its Songwe Hill project and Pulawy separation plant. More recently, £3 million was raised to support the development of the HyProMag recycling business.
“[The funding] strengthens the balance sheet in a crucial period as we continue to evaluate opportunities for rolling out HyProMag operations in additional jurisdictions and other new growth opportunities,” said chief executive Will Dawes.
Empire Metals ended the year by winning 'Exploration Discovery of the Year' for its Pitfield titanium project in Western Australia. In August, the company reported high-grade drill results from the Thomas prospect, with a central zone averaging 6% TiO₂ over a 3.6km strike length.
Shaun Bunn, managing director, said the results “confirm the exceptional scale and grade of titanium mineralisation at Thomas” and enabled an accelerated push toward a maiden resource estimate.
Xeros Technology Group rebounded from multi-year lows, with shares hitting an 18-month high in October after signing a development and product launch agreement with one of the world’s top-ten washing machine manufacturers. The agreement covers a joint project to commercialise machines featuring Xeros’ XDrum and XOrbs technology.
Once launched, Xeros expects to earn royalties per machine and additional revenue from XOrbs sales, with the potential for mass-market distribution under the manufacturer’s brand.
ImmuPharma shares jumped in September after it filed a new patent for P140, a first-in-class “immunormaliser” targeting Type M immune disorders. The application covers both a diagnostic and therapy, offering potential exclusivity for up to 20 years. The company said it had entered discussions with several global pharmaceutical groups.
Chief executive Tim McCarthy described the development as “a game changer” that expanded the scope of P140 and supported ongoing partner discussions.
AIM top risers
- Fiinu +1680%
- Strategic Minerals +1230%
- Mkango Resources +500%
- Empire Metals +479%
- Xeros Technology +367%
- Guardian Metal Resources +360%
- Westmount Energy +338%
- ImmuPharma +335%
- Thor Explorations +335%
- Shield Therapeutics +315%
- Greatland Resources +315%
- Borders & Southern Petroleum +315%
- Haydale Graphene Industries +302%
- Bezant Resource 243%
- Hardide +229%
Fallers
- Futura Medical -96%
- Mirriad Advertising -96%
- Ethernity Networks 95%
- The Revel Collective 95%
- Polarean Imaging 94%
- Premier African Minerals 92%
- Litigation Capital Management 91%
- Cellbxhealth -90%
- Nativo Resources -89%
- Tissue Regenix Group -88%
- EQTEC -86%
- Thruvision Group -85%
- Synergia Energy -85%
- Revolution Beauty Group -83%
- Oxford BioDynamics -83%
- Data from Sharecope, 22/12/25
AIM fallers
AIM’s sharpest fallers in 2025 were hit by a combination of strategic uncertainty, cash constraints, slow progress and – in some cases – a looming departure from the market altogether.
Waxing and waning progress should not be a surprise for the LSE's smallest companies, and most investors in this end of the market are aware of the risk/reward tradeoff.
Futura Medical has found itself at the end of the year with a new CEO and a freshly topped-up bank balance.
Alex Duggan was appointed interim chief executive in August and his strategic review focused on maximising value from its two key assets, Eroxon Intense and WSD4000.
While acknowledging that initial sales of Eroxon – its topical erectile dysfunction treatment, which is available in 25 countries – had been slower than expected, Duggan noted that “markets of this nature often take time to develop”.
Futura has raised £2.75 million to support ongoing product development and stabilise operations, with regulatory approvals for Eroxon Intense expected in 2026 and further studies on WSD4000 scheduled for the same year.
Mirriad Advertising plunged in April after warning it may soon run out of money and could enter administration within days unless fresh funding is secured.
The AIM-quoted virtual product placement specialist, which had a cash balance of £2.7 million and monthly outgoings nearing £675,000, later revealed that talks over a potential takeover had collapsed at the end of April, leaving the board scrambling for alternatives to keep the business afloat.
More recently, it reported that cash stood at £1 million at the end of November after cost-cutting measures were introduced, but that trading conditions remained difficult, with a 73% fall in revenue to around £0.4 million for the year.
The Revel Collective shares dropped over 50% in a day after warning in December that its formal sale process was unlikely to deliver any return to shareholders. The group operates the Revolution, Revolución de Cuba, and Peach Pubs brands.
Polarean Imaging said in November it would leave AIM to reduce listing costs and increase fundraising flexibility. The company, which develops lung-imaging technology, said public markets were not reflecting its value and that it needs $20 million to reach profitability.
Premier African Minerals raised £500,000 in November to fund short-term operational needs at its Zulu lithium project in Zimbabwe. Shares have fallen 84% since January as the company works toward commissioning a new flotation plant.